Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transplant Toxicities

Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy

Bone Marrow Transplantation volume 50, pages 727–733 (2015)Cite this article

Subjects

Abstract

This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (⩾1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P=0.65; bacterial infection, 44 vs 41%, P=0.68; and fungal infection, 6 vs 8%, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ⩾1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799–805.

    Article  CAS  Google Scholar 

  2. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.

    Article  CAS  Google Scholar 

  3. Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010; 95: 476–484.

    Article  CAS  Google Scholar 

  4. Tachibana T, Tanaka M, Takasaki H, Numata A, Maruta A, Ishigatsubo Y et al. Pre-SCT serum ferritin is a prognostic factor in adult AML, but not ALL [letter]. Bone Marrow Transplant 2011; 46: 1268–1269.

    Article  CAS  Google Scholar 

  5. Tachibana T, Takasaki H, Tanaka M, Maruta A, Hyo R, Ishigatsubo Y et al. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. Bone Marrow Transplant 2011; 46: 150–151.

    Article  CAS  Google Scholar 

  6. Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 195–204.

    Article  Google Scholar 

  7. Kanda J, Mizumoto C, Ichinohe T, Kawabata H, Saito T, Yamashita K et al. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 208–216.

    Article  CAS  Google Scholar 

  8. Tanaka M, Tachibana T, Numata A, Takasaki H, Matsumoto K, Maruta A et al. A prognostic score with pretransplant serum ferritin and disease status predicts outcome following reduced-intensity SCT. Bone Marrow Transplant 2012; 47: 596–597.

    Article  CAS  Google Scholar 

  9. Tachibana T, Tanaka M, Takasaki H, Numata A, Ito S, Watanabe R et al. Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies. Int J Hematol 2011; 93: 368–374.

    Article  CAS  Google Scholar 

  10. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004; 34: 505–509.

    Article  CAS  Google Scholar 

  11. Bullen JJ, Rogers HJ, Spalding PB, Ward CG . Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006; 55: 251–258.

    Article  CAS  Google Scholar 

  12. van Asbeck BS, Marx JJ, Struyvenberg A, van Kats JH, Verhoef J . Effect of iron (III) in the presence of various ligands on the phagocytic and metabolic activity of human polymorphonuclear leukocytes. J Immunol 1984; 132: 851–856.

    CAS  PubMed  Google Scholar 

  13. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  Google Scholar 

  14. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    Article  Google Scholar 

  15. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.

    Article  Google Scholar 

  16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    Google Scholar 

  17. Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

    Article  Google Scholar 

  18. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  19. Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.

    Article  CAS  Google Scholar 

  20. Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T . Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 2001; 113: 836–838.

    Article  CAS  Google Scholar 

  21. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310–316.

    Article  CAS  Google Scholar 

  22. Lim ZY, Fiaccadori V, Gandhi S, Hayden J, Kenyon M, Ireland R et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res 2010; 34: 723–727.

    Article  CAS  Google Scholar 

  23. Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kondo T et al. Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2013; 97: 109–116.

    Article  CAS  Google Scholar 

  24. Grossekatthofer M, Guclu ED, Lawitschka A, Matthes-Martin S, Mann G, Minkov M et al. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. Ann Hematol 2013; 92: 1121–1128.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    M Tanaka, H Kanamori, K Matsumoto, T Tachibana & A Numata

  2. Department of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    T Tachibana & E Yamazaki

  3. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    A Numata, S Fujisawa & H Sakamaki

  4. Division of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan

    K Ohashi & T Kobayashi

  5. Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Japan

    C Nakaseko

  6. Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    Y Kanda

  7. Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    J Ooi & S Takahashi

  8. Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

    T Sakura

  9. Department of Hematology, Narita Red Cross Hospital, Narita, Japan

    N Aotsuka

  10. Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan

    M Onoda

  11. Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan

    S Machida

  12. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    J Kato & S Okamoto

  13. Division of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

    K Usuki

  14. Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    R Watanabe

  15. Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan

    J Taguchi

  16. Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

    S Yano

  17. Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan

    T Saito

Authors
  1. M Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Tachibana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Numata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Nakaseko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Ooi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Sakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. N Aotsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Onoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Machida
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. J Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. K Usuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. R Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. S Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. T Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. S Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. H Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. S Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Kanto Study Group for Cell Therapy

Corresponding author

Correspondence to M Tanaka.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author Contributions

MT and HK designed the study. MT prepared and analyzed data. MT had primary responsibility for drafting the manuscript. KM, TT, AN, KO, TK, CN, YK, EY, SF, JO, T Sakura, NA, MO, SM, JK, KU, RW, JT, SY, T Saito, ST, HS and SO interpreted data and critically reviewed the manuscript. All authors contributed equally to the interpretation of data, manuscript preparation and approval of the final report.

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanaka, M., Kanamori, H., Matsumoto, K. et al. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transplant 50, 727–733 (2015). https://doi.org/10.1038/bmt.2015.17

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.17

This article is cited by

Search

Advanced search

Quick links